Literature DB >> 12887410

Binding characteristics of [3H]14-methoxymetopon, a high affinity mu-opioid receptor agonist.

Mariana Spetea1, Fanni Tóth, Johannes Schütz, Ferenc Otvös, Géza Tóth, Sandor Benyhe, Anna Borsodi, Helmut Schmidhammer.   

Abstract

The highly potent micro -opioid receptor agonist 14-methoxymetopon (4,5alpha-epoxy-3-hydroxy-14beta-methoxy-5beta,17-dimethylmorphinan-6-one) was prepared in tritium labelled form by a catalytic dehalogenation method resulting in a specific radioactivity of 15.9 Ci/mmol. Opioid binding characteristics of [3H]14-methoxymetopon were determined using radioligand binding assay in rat brain membranes. [3H]14-Methoxymetopon specifically labelled a single class of opioid sites with affinity in low subnanomolar range (Ki = 0.43 nm) and maximal number of binding sites of 314 fmol/mg protein. Binding of [3H]14-methoxymetopon was inhibited by ligands selective for the micro -opioid receptor with high potency, while selective kappa-opioids and delta-opioids were weaker inhibitors. 14-Methoxymetopon increased guanosine-5'-O-(3-[35S]thio)-triphosphate ([35S]GTPgammaS) binding with an EC50 of 70.9 nm, thus, providing evidence for the agonist character of this ligand. The increase of [35S]GTPgammaS binding was inhibited by naloxone and selective micro -opioid antagonists, indicating a micro -opioid receptor-mediated action. [3H]14-Methoxymetopon is one of the few nonpeptide mu-opioid receptor agonists available in radiolabelled form up to now. Due to its high affinity and selectivity, high stability and extremely low nonspecific binding (<10%), this radioligand would be an important and useful tool in probing mu-opioid receptor mechanisms, as well as to promote a further understanding of the opioid system at the cellular and molecular level.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 12887410     DOI: 10.1046/j.1460-9568.2003.02744.x

Source DB:  PubMed          Journal:  Eur J Neurosci        ISSN: 0953-816X            Impact factor:   3.386


  6 in total

1.  Psychedelics and the human receptorome.

Authors:  Thomas S Ray
Journal:  PLoS One       Date:  2010-02-02       Impact factor: 3.240

Review 2.  Most recent developments and modifications of 14-alkylamino and 14-alkoxy-4,5-epoxymorphinan derivatives.

Authors:  L Stavitskaya; A Coop
Journal:  Mini Rev Med Chem       Date:  2011-10       Impact factor: 3.862

3.  In vitro and in vivo pharmacological profile of the 5-benzyl analogue of 14-methoxymetopon, a novel mu opioid analgesic with reduced propensity to alter motor function.

Authors:  Mariana Spetea; Catalina R Bohotin; Muhammad F Asim; Kurt Stübegger; Helmut Schmidhammer
Journal:  Eur J Pharm Sci       Date:  2010-06-18       Impact factor: 4.384

4.  Synthesis and pharmacological activities of 6-glycine substituted 14-phenylpropoxymorphinans, a novel class of opioids with high opioid receptor affinities and antinociceptive potencies.

Authors:  Mariana Spetea; Petra Windisch; Yan Guo; Indre Bileviciute-Ljungar; Johannes Schütz; Muhammad Faheem Asim; Ilona P Berzetei-Gurske; Pal Riba; Kornel Kiraly; Susanna Fürst; Mahmoud Al-Khrasani; Helmut Schmidhammer
Journal:  J Med Chem       Date:  2011-01-14       Impact factor: 7.446

Review 5.  Development of 5-Substituted N-Methylmorphinan-6-ones as Potent Opioid Analgesics with Improved Side-Effect Profile.

Authors:  Helmut Schmidhammer; Mariana Spetea
Journal:  Int J Med Chem       Date:  2012-06-17

6.  14-Methoxymetopon, a highly potent mu opioid agonist, biphasically affects ethanol intake in Sardinian alcohol-preferring rats.

Authors:  Valentina Sabino; Pietro Cottone; Luca Steardo; Helmut Schmidhammer; Eric P Zorrilla
Journal:  Psychopharmacology (Berl)       Date:  2007-03-08       Impact factor: 4.415

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.